Autologous cord blood cell therapy for neonatal hypoxic-ischaemic encephalopathy: a pilot study for feasibility and safety.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
12 03 2020
12 03 2020
Historique:
received:
30
10
2019
accepted:
03
02
2020
entrez:
14
3
2020
pubmed:
14
3
2020
medline:
24
11
2020
Statut:
epublish
Résumé
Neonatal hypoxic-ischaemic encephalopathy (HIE) is a serious condition; many survivors develop neurological impairments, including cerebral palsy and intellectual disability. Preclinical studies show that the systemic administration of umbilical cord blood cells (UCBCs) is beneficial for neonatal HIE. We conducted a single-arm clinical study to examine the feasibility and safety of intravenous infusion of autologous UCBCs for newborns with HIE. When a neonate was born with severe asphyxia, the UCB was collected, volume-reduced, and divided into three doses. The processed UCB was infused at 12-24, 36-48, and 60-72 hours after the birth. The designed enrolment was six newborns. All six newborns received UCBC therapy strictly adhering to the study protocol together with therapeutic hypothermia. The physiological parameters and peripheral blood parameters did not change much between pre- and postinfusion. There were no serious adverse events that might be related to cell therapy. At 30 days of age, the six infants survived without circulatory or respiratory support. At 18 months of age, neurofunctional development was normal without any impairment in four infants and delayed with cerebral palsy in two infants. This pilot study shows that autologous UCBC therapy is feasible and safe.
Identifiants
pubmed: 32165664
doi: 10.1038/s41598-020-61311-9
pii: 10.1038/s41598-020-61311-9
pmc: PMC7067794
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
4603Références
Dammann, O., Ferriero, D. & Gressens, P. Neonatal encephalopathy or hypoxic-ischemic encephalopathy? Appropriate terminology matters. Pediatr. Res. 70, 1–2 (2011).
pubmed: 21654279
doi: 10.1203/PDR.0b013e318223f38d
pmcid: 21654279
Volpe, J. J. Neonatal encephalopathy: An inadequate term for hypoxic-ischemic encephalopathy. Ann. Neurol. 72, 156–166 (2012).
pubmed: 22926849
doi: 10.1002/ana.23647
pmcid: 22926849
Shankaran, S. et al. National Institute of Child H, Human Development Neonatal Research Network. Whole-body hypothermia for neonates with hypoxic-ischemic encephalopathy. N. Engl. J. Med. 353, 1574–1584 (2005).
pubmed: 16221780
doi: 10.1056/NEJMcps050929
pmcid: 16221780
Gluckman, P. D. et al. Selective head cooling with mild systemic hypothermia after neonatal encephalopathy: multicentre randomised trial. Lancet 365, 663–670 (2005).
pubmed: 15721471
doi: 10.1016/S0140-6736(05)17946-X
pmcid: 15721471
Gunn, A. J., Gunn, T. R., Gunning, M. I., Williams, C. E. & Gluckman, P. D. Neuroprotection with prolonged head cooling started before postischemic seizures in fetal sheep. Pediatrics 102, 1098–1106 (1998).
pubmed: 9794940
doi: 10.1542/peds.102.5.1098
pmcid: 9794940
Higgins, R. D. et al. Hypothermia and other treatment options for neonatal encephalopathy: an executive summary of the Eunice Kennedy Shriver NICHD Workshop. J. Pediatr. 159, 851–858 (2011).
pubmed: 21875719
pmcid: 3263823
doi: 10.1016/j.jpeds.2011.08.004
Tsuji, M., Sizonenko, S. V. & Baud, O. Editorial: Preventing developmental brain injury - from animal models to clinical trials. Front. Neurol. 19(10), 775 (2019).
doi: 10.3389/fneur.2019.00775
Jantzie, L., Scafidi, J. & Robinson, S. Stem cells and cell-based therapies for cerebral palsy: a call for rigor. Pediatr. Res. 83, 345–355 (2018).
pubmed: 28922350
doi: 10.1038/pr.2017.233
pmcid: 28922350
Bennet, L. et al. Cell therapy for neonatal hypoxia-ischemia and cerebral palsy. Ann. Neurol. 71, 589–600 (2012).
pubmed: 22522476
doi: 10.1002/ana.22670
pmcid: 22522476
Liao, Y., Cotten, M., Tan, S., Kurtzberg, J. & Cairo, M. S. Rescuing the neonatal brain from hypoxic injury with autologous cord blood. Bone Marrow Transplant. 48, 890–900 (2013).
pubmed: 22964590
doi: 10.1038/bmt.2012.169
pmcid: 22964590
Meier, C. et al. Spastic paresis after perinatal brain damage in rats is reduced by human cord blood mononuclear cells. Pediatr. Res. 59, 244–249 (2006).
pubmed: 16439586
doi: 10.1203/01.pdr.0000197309.08852.f5
pmcid: 16439586
de Paula, S., Greggio, S., Marinowic, D. R., Machado, D. C. & DaCosta, J. C. The dose-response effect of acute intravenous transplantation of human umbilical cord blood cells on brain damage and spatial memory deficits in neonatal hypoxia-ischemia. Neuroscience 210, 431–441 (2012).
pubmed: 22441035
doi: 10.1016/j.neuroscience.2012.03.009
pmcid: 22441035
Pimentel-Coelho, P. M. et al. Human cord blood transplantation in a neonatal rat model of hypoxic-ischemic brain damage: functional outcome related to neuroprotection in the striatum. Stem Cells Dev. 19, 351–358 (2010).
pubmed: 19296724
doi: 10.1089/scd.2009.0049
pmcid: 19296724
Yasuhara, T. et al. Mannitol facilitates neurotrophic factor up-regulation and behavioural recovery in neonatal hypoxic-ischemic rats with human umbilical cord blood grafts. J. Cell Mol. Med. 14, 914–921 (2010).
pubmed: 20569276
pmcid: 3823123
doi: 10.1111/j.1582-4934.2008.00671.x
Rosenkranz, K. et al. The chemokine SDF-1/CXCL12 contributes to the ‘homing’ of umbilical cord blood cells to a hypoxic-ischemic lesion in the rat brain. J. Neurosci. Res. 88, 1223–1233 (2010).
pubmed: 19937807
pmcid: 19937807
Dalous, J. et al. Use of human umbilical cord blood mononuclear cells to prevent perinatal brain injury: a preclinical study. Stem Cells Dev. 22, 169–179 (2012).
pubmed: 22621245
doi: 10.1089/scd.2012.0183
Bae, S. H. et al. Long-lasting paracrine effects of human cord blood cells on damaged neocortex in an animal model of cerebral palsy. Cell Transplant. 21, 2497–2515 (2012).
pubmed: 22524897
doi: 10.3727/096368912X640457
Tsuji, M. et al. Effects of intravenous administration of umbilical cord blood CD34
pubmed: 24444827
doi: 10.1016/j.neuroscience.2014.01.018
Hattori, T. et al. Administration of umbilical cord blood cells transiently decreased hypoxic-ischemic brain injury in neonatal rats. Dev. Neurosci. 37, 95–104 (2015).
pubmed: 25720519
doi: 10.1159/000368396
Kadam, S. D. et al. Systemic injection of CD34
pubmed: 25121827
doi: 10.1089/scd.2014.0135
pmcid: 25121827
Drobyshevsky, A. et al. Human umbilical cord blood cells ameliorate motor deficits in rabbits in a cerebral palsy model. Dev. Neurosci. 37, 349–362 (2015).
pubmed: 25791742
pmcid: 4908833
doi: 10.1159/000374107
Ohshima, M. et al. Evaluations of intravenous administration of CD34
pubmed: 28103599
doi: 10.1159/000454830
pmcid: 28103599
Li, J. T. et al. Preterm white matter brain injury is prevented by early administration of umbilical cord blood cells. Exp. Neurol. 283, 179–187 (2016).
pubmed: 27317990
doi: 10.1016/j.expneurol.2016.06.017
pmcid: 27317990
Kidani, Y. et al. The therapeutic effect of CD133
pubmed: 27287679
doi: 10.1016/j.lfs.2016.06.004
pmcid: 27287679
McDonald, C. A. et al. Effects of umbilical cord blood cells, and subtypes, to reduce neuroinflammation following perinatal hypoxic-ischemic brain injury. J. Neuroinflammation 15, 47 (2018).
pubmed: 29454374
pmcid: 5816393
doi: 10.1186/s12974-018-1089-5
Cotten, C. M. et al. Feasibility of autologous cord blood cells for infants with hypoxic-ischemic encephalopathy. J. Pediatr. 164, 973–979 (2014).
pubmed: 24388332
doi: 10.1016/j.jpeds.2013.11.036
pmcid: 24388332
Kono, Y. et al. Developmental assessment of VLBW infants at 18 months of age: A comparison study between KSPD and Bayley III. Brain Dev. 38, 377–385 (2016).
pubmed: 26542468
doi: 10.1016/j.braindev.2015.10.010
pmcid: 26542468
Nabetani, M., Shintaku, H. & Hamazaki, T. Future perspectives of cell therapy for neonatal hypoxic-ischemic encephalopathy. Pediatr. Res. 83, 356–363 (2018).
pubmed: 29016557
doi: 10.1038/pr.2017.260
pmcid: 29016557
Mazzanti, B. et al. Fully automated, clinical-grade bone marrow processing: a single-centre experience. Blood Transfus. 15, 577–584 (2017).
pubmed: 27723450
pmcid: 5649968
Li, K. et al. Human neonatal blood: stem cell content, kinetics of CD34
pubmed: 10027731
doi: 10.1046/j.1365-2141.1999.01147.x
pmcid: 10027731
Kim, J. P., Lee, Y. H., Lee, Y. A. & Kim, Y. D. A comparison of the kinetics of nucleated cells and CD34
pubmed: 17382254
doi: 10.1016/j.bbmt.2006.12.446
pmcid: 17382254
Tsuda, K. et al. Therapeutic hypothermia for neonatal encephalopathy: a report from the first 3 years of the Baby Cooling Registry of Japan. Sci. Rep. 7, 39508 (2017).
pubmed: 28051172
pmcid: 5209702
doi: 10.1038/srep39508
Sun, J. et al. Differences in quality between privately and publicly banked umbilical cord blood units: a pilot study of autologous cord blood infusion in children with acquired neurologic disorders. Transfusion 50, 1980–1987 (2010).
pubmed: 20546200
doi: 10.1111/j.1537-2995.2010.02720.x
pmcid: 20546200
Sun, J. M. et al. Effect of autologous cord blood infusion on motor function and brain connectivity in young children with cerebral palsy: a randomized, placebo-controlled trial. Stem Cells Transl. Med. 6, 2071–2078 (2017).
pubmed: 29080265
pmcid: 5702515
doi: 10.1002/sctm.17-0102
Tsuji, M. Hematopoietic stem cells for perinatal brain injury. In: Shinataku, H. ed. Cell Therapy for Perinatal Brain Injury. P45–56. Springer Nature Singapore Pte Ltd. (2018).
Uemura, M., Kasahara, Y., Nagatsuka, K. & Taguchi, A. Cell-based therapy to promote angiogenesis in the brain following ischemic damage. Curr. Vasc. Pharmacol. 10, 285–288 (2012).
pubmed: 22239630
doi: 10.2174/157016112799959369
pmcid: 22239630
Donega, V. et al. Intranasal mesenchymal stem cell treatment for neonatal brain damage: long-term cognitive and sensorimotor improvement. PLoS One 8, e51253 (2013).
pubmed: 23300948
pmcid: 3536775
doi: 10.1371/journal.pone.0051253
Herz, J. et al. Interaction between hypothermia and delayed mesenchymal stem cell therapy in neonatal hypoxic-ischemic brain injury. Brain Behav. Immun. 70, 118–130 (2018).
pubmed: 29454023
doi: 10.1016/j.bbi.2018.02.006
Park, W. S. et al. Hypothermia augments neuroprotective activity of mesenchymal stem cells for neonatal hypoxic-ischemic encephalopathy. PLoS One 10, e0120893 (2015).
pubmed: 25816095
pmcid: 4376738
doi: 10.1371/journal.pone.0120893
Ahn, S. Y., Chang, Y. S., Sung, D. K., Sung, S. I. & Park, W. S. Hypothermia broadens the therapeutic time window of mesenchymal stem cell transplantation for severe neonatal hypoxic ischemic encephalopathy. Sci. Rep. 8, 7665 (2018).
pubmed: 29769612
pmcid: 5955959
doi: 10.1038/s41598-018-25902-x
Perlman, J. M. et al. Neonatal resuscitation chapter. Part 11: Neonatal resuscitation: International consensus on cardiopulmonary resuscitation and emergency cardiovascular care science with treatment recommendations. Circulation 122, S516–538 (2010).
pubmed: 20956259
doi: 10.1161/CIRCULATIONAHA.110.971127
pmcid: 20956259
Tsuji, M. & Shintaku, H. Clinical trial of autologous cord blood cell therapy for neonatal hypoxic-ischemic encephalopathy (HIE). In: Shinataku, H. ed. Cell Therapy for Perinatal Brain Injury. P1–15. Springer Nature Singapore Pte Ltd. (2018).
Schwandt, S., Korschgen, L., Peters, S. & Kogler, G. Cord blood collection and processing with hydroxyethyl starch or non-hydroxyethyl starch. Cytotherapy 18, 642–52 (2016).
pubmed: 27059201
doi: 10.1016/j.jcyt.2016.02.003
pmcid: 27059201